Holen Sie sich die Stockscreener-App
17.20
2.63%
0.44
Handel nachbörslich:
17.25
0.05
+0.29%
Schlusskurs vom Vortag:
$16.76
Offen:
$16.83
24-Stunden-Volumen:
2.89M
Relative Volume:
0.94
Marktkapitalisierung:
$4.10B
Einnahmen:
$426.45M
Nettoeinkommen (Verlust:
$197.67M
KGV:
20.98
EPS:
0.82
Netto-Cashflow:
$110.10M
1W Leistung:
-7.23%
1M Leistung:
-7.08%
6M Leistung:
+6.97%
1J Leistung:
-0.41%
1-Tages-Spanne:
$16.62
$17.27
1-Wochen-Bereich:
$14.62
$17.52
52-Wochen-Spanne:
$14.62
$25.67
Adma Biologics Inc Stock (ADMA) Company Profile
Firmenname
Adma Biologics Inc
Sektor
Branche
Telefon
(201) 478-5552
Adresse
C/O ADMA BIOLOGICS, INC., RAMSEY
Vergleichen Sie ADMA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
17.20 | 4.00B | 426.45M | 197.67M | 110.10M | 0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-07-19 | Fortgesetzt | Raymond James | Strong Buy |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2021-11-11 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-11-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-04 | Eingeleitet | Jefferies | Buy |
| 2019-04-15 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-07 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-12-11 | Bestätigt | Maxim Group | Buy |
| 2017-11-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-01-23 | Hochstufung | Maxim Group | Hold → Buy |
| 2016-08-01 | Herabstufung | Maxim Group | Buy → Hold |
| 2016-07-25 | Bestätigt | Maxim Group | Buy |
| 2015-05-13 | Bestätigt | Maxim Group | Buy |
| 2014-12-08 | Eingeleitet | Oppenheimer | Outperform |
| 2014-12-01 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Adma Biologics Inc Aktie (ADMA) Neueste Nachrichten
ADMA Biologics (NASDAQ:ADMA) Is Posting Healthy Earnings, But It Is Not All Good News - 富途牛牛
Why ADMA Biologics Inc. stock attracts strong analyst attentionFree Double Return Watchlist - thegnnews.com
ADMA projects $1.1B revenue before 2030 as yield enhancement drives margin expansion and ASCENIV growth - MSN
How did ADMA's revenue surge in Q4 2024 impact its profitability? - AInvest
ADMA Biologics: Optionality With SG-001 And A Vertically Integrated IG Platform - Seeking Alpha
Insider Sellers Might Regret Selling ADMA Biologics Shares at a Lower Price Than Current Market Value - 富途牛牛
ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum - MSN
ADMA Biologics Thrives With Blockbuster Growth And New FDA Edge - Finimize
ADMA Biologics' Stock Underperforms After Q1 Results - AInvest
ADMA Biologics: A Better Quarter Than Headline Numbers (NASDAQ:ADMA) - Seeking Alpha
ADMA Biologics, Inc. (NASDAQ:ADMA) Q2 2025 Earnings Call Transcript - Insider Monkey
ADMA Biologics 2025 Q2 Earnings Strong Performance as Net Income Rises 6.7% - AInvest
ADMA Biologics Secures $300M Credit Agreement with JPMorgan - AInvest
ADMA Biologics Earnings Call Highlights Robust Growth - TipRanks
ADMA Biologics Rides ASCENIV Demand To Higher Guidance - Finimize
ADMA Biologics Outpaces Expectations With Upbeat Growth Plans - Finimize
Noteworthy Thursday Option Activity: ADMA, SMMT, ICHR - Nasdaq
ADMA Biologics Sees Promising Gains Amid Strategic Shifts and Rising Market Trends - timothysykes.com
Plasma Derived Medicine Market to Reach USD 37.4 Billion by 2034, Growing at 8.05% CAGR - GlobeNewswire Inc.
ADMA Beats On Q2 Earnings And Revenues, Asceniv Drives Momentum - Barchart.com
Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Earnings call transcript: ADMA Biologics Q2 2025 misses earnings expectations By Investing.com - Investing.com South Africa
Earnings call transcript: ADMA Biologics Q2 2025 misses earnings expectations - Investing.com
ADMA Biologics Inc earnings missed, revenue fell short of estimates By Investing.com - Investing.com UK
Adma Biologics (ADMA) Q2 Revenue Up 14% - AOL.com
ADMA Biologics Reports Strong Q2 2025 Results - TipRanks
ADMA Biologics Q2 2025 Earnings Call Transcript - MarketBeat
ADMA Biologics (ADMA) Projects Significant Growth with Yield Process and Refinancing - GuruFocus
ADMA Biologics: A Tale of Two Narratives—Strong Fundamentals vs. a Pessimistic Rating - AInvest
ADMA Biologics' Q2 2025: Unraveling Contradictions in Yield Enhancements, Reimbursement, and Demand Dynamics - AInvest
ADMA Biologics Q2 2025 Earnings Call Transcript Review - AInvest
ADMA Biologics' Q2 2025 Earnings and Strategic Outlook: Navigating Insider Sales and Risk Disclosures for Long-Term Value - AInvest
ADMA Biologics Inc earnings missed, revenue fell short of estimates - Investing.com
Transcript : ADMA Biologics, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Adma Biologics (ADMA) Q2 Earnings and Revenues Beat Estimates - Yahoo Finance
Adma Biologics: Q2 Earnings Snapshot - San Antonio Express-News
Adma Biologics Q2 Earnings: Impressive Growth in Net Income and RevenueNews and Statistics - IndexBox
ADMA BIOLOGICS, INC. SEC 10-Q Report - TradingView
Why ADMA Biologics Shares Are Under Pressure - TipRanks
ADMA Biologics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Adma Biologics reports Q2 EPS 14c, consensus 14c - TipRanks
ADMA Biologics Reports Q2 EPS of $0.14, Revenue of $122M Exceeds Expectations - AInvest
ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update - The Manila Times
ADMA Biologics Reports 14% YoY Revenue Growth and Significant Financial Milestones in 2Q 2025 - Quiver Quantitative
Finanzdaten der Adma Biologics Inc-Aktie (ADMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):